In summary, this study integrated information from all databases and adopted the network pharmacology method to explain the potential pharmacological mechanism of CKI therapy for lung adenocarcinoma, which involved a variety of compound targets, biological processes, molecular functions, and signaling pathways, and was also verified by molecular docking. Here, CHKA is linked to lung adenocarcinoma.